Organophosphate-induced delayed neuropathy

Organophosphate-induced delayed neuropathy is a toxic distal dying-back axonopathy of the peripheral and central nervous systems that appears 10 to 21 days after exposure to neuropathic organophosphorus esters such as tri-ortho-cresyl phosphate, through inhibition and aging of neuropathy target esterase, now designated PNPLA6.

It is a rare consequence of poisoning rather than a common occupational disease, but the 1930 Jamaica ginger outbreak in the United States affected an estimated 20,000 to 50,000 people and left many with permanent foot drop, and the 1959 Moroccan cooking-oil episode involved about 10,000 cases.

Terminology and classification

• Organophosphate-induced delayed neuropathy is a toxic axonopathy of the central and peripheral nervous systems that appears one to three weeks after exposure to neuropathic organophosphorus esters.
• It is also called organophosphate-induced delayed polyneuropathy, and the two names describe the same entity, although the polyneuropathy form emphasises the peripheral component.
• The condition belongs to the group of distal dying-back axonopathies that also includes hexacarbon neuropathy from n-hexane and acrylamide neuropathy.
• ICD-10 has no dedicated code, and cases are classified under G62.2 for polyneuropathy due to other toxic agents, while ICD-11 places toxic polyneuropathies in chapter 08 on diseases of the nervous system.
• The MONDO concept MONDO:0957912 and the Wikidata identifier Q7102094 provide cross-database mapping, whereas Orphanet does not list the disorder because it is an acquired toxic condition rather than a rare disease.
• Historical synonyms include jake paralysis, jake leg and ginger jake paralysis, all coined after the 1930 outbreak caused by adulterated Jamaica ginger extract in the United States.
• The word delayed distinguishes the condition from the acute cholinergic crisis and from the intermediate syndrome, both of which occur within hours to days of poisoning.

History

• The first large outbreak began in 1930 during Prohibition, when a medicinal extract of Jamaican ginger was adulterated with tri-ortho-cresyl phosphate to circumvent alcohol restrictions.
• Officers of the United States Public Health Service, including Smith, Elvove and Frazier, identified tri-ortho-cresyl phosphate as the adulterant in 1930 and published the finding in Public Health Reports.
• Estimates of the number affected range from about 20,000 to 50,000 people across the southern and midwestern states, and many were left with permanent foot drop and gait disorder.
• Contaminated abortifacient preparations containing apiol produced smaller European outbreaks in the 1930s, and adulterated cooking oil caused about 10,000 cases in Morocco in 1959.
• M. K. Johnson identified neuropathy target esterase in 1969 and showed that phosphorylation followed by aging of the enzyme correlated with neuropathic potential.
• A 47-year follow-up of patients with Jamaica ginger paralysis, published by Morgan and Penovich in 1978, documented persistent distal weakness and sensory loss decades after exposure.
• Biallelic mutations in PNPLA6, the gene encoding neuropathy target esterase, were shown in the 2000s to cause hereditary spastic paraplegia type 39, linking the toxicology to inherited neurodegeneration.

Epidemiology

• No population-based incidence exists because the disorder is not notifiable, and estimates rely on poison centre series, outbreak reports and occupational surveillance.
• In the 1930 outbreak an estimated 20,000 to 50,000 people were affected, making it one of the largest toxic neuropathies recorded in history.
• The 1959 Moroccan outbreak involved roughly 10,000 people who consumed cooking oil adulterated with lubricating oil containing tri-ortho-cresyl phosphate.
• Among people with acute organophosphate poisoning, delayed neuropathy is uncommon, and the risk is highest with tri-ortho-cresyl phosphate and with phosphoramidate and phosphite esters rather than with dimethyl insecticides.
• Occupational risk is concentrated in pesticide formulation, aircraft maintenance and chemical manufacturing, and protective equipment reduces but does not eliminate exposure.
• Unintentional acute pesticide poisoning was estimated at 385 million cases and about 11,000 deaths each year worldwide in a 2020 analysis, although only a small fraction develops delayed neuropathy.
• Surveillance data come from the Agency for Toxic Substances and Disease Registry case studies updated in 2022, from WHO International Programme on Chemical Safety criteria and from national poison registries.

• The World Health Organization estimates about 3 million acute organophosphate poisonings and 300,000 deaths worldwide each year, and delayed neuropathy is reported in well under 1 per cent of survivors.

Pathophysiology

• Neuropathy target esterase is inhibited by phosphorylation of its active-site serine, and the enzyme, now designated PNPLA6, is the principal molecular target of neuropathic organophosphates.
• Only esters whose phosphorylated enzyme undergoes aging, the loss of an alkyl group, produce axonopathy, and the rate of aging predicts neuropathic potency.
• Aging converts the enzyme adduct into a permanently charged species that cannot be reactivated, so recovery requires synthesis of new enzyme.
• The structural lesion is a distal dying-back axonopathy in which the longest and largest myelinated fibres degenerate first, producing a length-dependent pattern.
• Secondary demyelination follows axonal loss, and in severe cases the anterior horn cells and the long ascending tracts of the spinal cord show degeneration.
• Tri-ortho-cresyl phosphate is a pro-toxin that requires hepatic metabolic activation to a cyclic saligenin phosphate, which is the proximate neurotoxic metabolite.
• Loss-of-function PNPLA6 variants cause hereditary spastic paraplegia type 39, Boucher-Neuhäuser syndrome and other neuroendocrine phenotypes, showing that the enzyme is required for axonal maintenance.

Clinical features

• After a latent interval of about 10 to 21 days, patients develop distal and symmetric weakness that begins in the legs in most cases.
• Foot drop and a high-stepping gait are early findings, and wrist drop follows in more severe exposures.
• Ankle reflexes are lost early, and a flaccid phase is later replaced by spasticity with hyperreflexia and extensor plantar responses as central tracts degenerate.
• Sensory involvement is usually mild, with distal numbness, pins and needles and painful cramps, and it rarely dominates the clinical picture.
• Cranial nerves and autonomic function are generally spared, although rare reports describe bulbar weakness and bladder dysfunction.
• Severe cases progress to quadriparesis with respiratory muscle weakness, and patients may require ventilatory support and wheelchair use.
• Named complications include ankle contractures, pressure injuries, falls with fractures, aspiration pneumonia, depression and loss of employment.

Diagnosis

• Diagnosis rests on a credible exposure history, a latent interval of one to three weeks and a distal symmetric motor neuropathy, and no formal consensus criteria have been adopted.
• Nerve conduction studies show reduced compound muscle action potentials with relatively preserved sensory potentials, and needle electromyography shows active denervation and chronic reinnervation.
• Reduced lymphocyte neuropathy target esterase activity has been used as a research biomarker, but it is not validated for routine clinical diagnosis.
• Spinal magnetic resonance imaging may show T2 hyperintensity in the posterior columns and pyramidal tracts in patients with central involvement.
• Differential diagnosis includes Guillain-Barré syndrome, which is ascending and areflexic with albuminocytological dissociation, and chronic inflammatory demyelinating polyneuropathy, which is relapsing and steroid-responsive.
• Other mimics are compressive or toxic myelopathy, amyotrophic lateral sclerosis, lead and n-hexane neuropathy, poliomyelitis, lathyrism and diabetic distal polyneuropathy.
• Recognition is delayed in mild cases and in regions without toxicology services, and exposure history must be elicited from workplace records, food sources and pesticide inventories.

Management

• No antidote reverses established neuropathy, and atropine with an oxime is indicated only for the acute cholinergic crisis, which it does not prevent.
• Management begins with removal from exposure, decontamination of skin and clothing and notification of occupational health services.
• Rehabilitation combines physiotherapy, ankle-foot orthoses, stretching and strengthening, together with a falls prevention assessment.
• Spasticity is treated with oral baclofen or tizanidine, and focal spasticity responds to botulinum toxin type A injections.
• Neuropathic pain responds partially to gabapentin, pregabalin, amitriptyline or duloxetine, and opioids are avoided because of dependence risk.
• Corticosteroids, intravenous immunoglobulin and plasma exchange have been tried without convincing benefit, and no randomised trial supports immunotherapy.
• Recovery is incomplete in most patients, with partial improvement over 12 to 24 months, persistent distal weakness and a high risk of long-term disability, as the 1978 follow-up showed.

• Foot drop is managed with ankle-foot orthoses and functional electrical stimulation of the common peroneal nerve, and gait training with walking aids reduces falls during the long recovery phase.

Research and controversies

• The aerotoxic syndrome hypothesis proposes that cabin air contaminated by engine oil containing tricresyl phosphate causes chronic neurological symptoms in aircrew, but the evidence remains contested.
• An association between organophosphate exposure and Gulf War illness has been debated for three decades, and cohort studies have not established causation.
• Neuropathy target esterase activity in lymphocytes and platelets is being evaluated as a biomarker of exposure, and standardisation across laboratories is still lacking.
• AAV-mediated PNPLA6 gene replacement is in preclinical development for hereditary spastic paraplegia type 39, and it has not yet been tested in toxic neuropathy.
• Small-molecule stabilisers of neuropathy target esterase are being explored as a complementary strategy, and no candidate has entered clinical trials for this indication.
• Whether mild neuropathy is underdiagnosed remains unresolved, because nerve conduction abnormalities may resolve while patients report persistent fatigue and gait difficulty.
• Regulatory limits for tricresyl phosphate in aircraft cabin air differ between jurisdictions, and there is no international occupational exposure limit for the neurotoxic isomers.